Expression of the oestrogen responsive protein pS2 in human breast cancer.
The trefoil peptide pS2 was discovered in a breast cancer cell line as a result of its oestrogen responsive character. The expression of pS2 in breast tumours in vivo is also likely to be an oestrogenic effect and as such, the presence of pS2 in oestrogen receptor positive breast cancer is evidence of an intact oestrogen response pathway and an indicator of putative hormone responsiveness. Consistent with this, clinical studies of breast cancer have revealed a correlation between pS2 expression and favourable tumour characteristics as well as response to endocrine therapy.
Balleine
R L
RL
Westmead Institute for Cancer Research, University of Sydney, Westmead Hospital, Australia.
Clarke
C L
CL
D001943:Breast Neoplasms / Q000378:metabolism*; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D006801:Humans; D011379:Prognosis; D011506:Proteins / Q000235:genetics*; D011980:Receptors, Progesterone / Q000096:biosynthesis; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins
D004967:Estrogens; D011506:Proteins; D011980:Receptors, Progesterone; C051838:TFF1 protein, human; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins